[[{“value”:”
CANNAVIGIA (by Vigia AG), a global pioneer in cannabis compliance software and consulting, is expanding its presence in the U.S. market, building on recent regulatory developments related to the potential rescheduling of medical cannabis to Schedule III. Although further regulatory shifts may take time, CANNAVIGIA is strategically positioned to support U.S. cannabis operators with advanced compliance solutions and international growth expertise in a rapidly evolving industry landscape.
As cannabis reform remains on the administration’s agenda, CANNAVIGIA is preparing to assist U.S. businesses in navigating compliance challenges and growth opportunities. CANNAVIGIA CEO Timo Bongartz, an invited speaker at MJBizCon, will take the stage in Las Vegas to discuss regulatory compliance and cross-border strategies. Additionally, Bongartz and the CANNAVIGIA team will be present at the expo at the booth of their close partner, AROYA by Addium Inc., where CANNAVIGIA will showcase its solutions and highlight its role as the exclusive distributor of AROYA in the EU, UK, Israel, and Switzerland.
At the expo, CANNAVIGIA will showcase its successful track record and strategic partnerships across European markets, including contributions to cannabis legalisation in Switzerland, Germany, Costa Rica, the Czech Republic, and other global regions. CANNAVIGIA is also preparing for its next funding round to drive global expansion and further enhance its market-leading compliance solutions, positioning itself to support U.S. operators as opportunities expand in the U.S., Germany, and across Europe.
Leveraging its extensive experience across regulated cannabis markets, CANNAVIGIA offers U.S. operators a comprehensive suite of compliance solutions, including support for Good Agricultural and Collection Practices (GACP), Good Manufacturing Practices (GMP), and Good Distribution Practices (GDP). CANNAVIGIA’s advanced track-and-trace software, designed to align with these rigorous standards, further ensures supply chain transparency and regulatory readiness for medical cannabis operations.
The reclassification of cannabis would represent an acknowledgment of its medicinal benefits, opening new avenues for clinical research and FDA-approved treatments. “Our commitment to supporting the cannabis industry is unwavering,” said Timo Bongartz, CEO of CANNAVIGIA. “As the U.S. moves towards greater regulatory flexibility, we’re positioned to be key compliance partners for American cannabis and pharmaceutical companies seeking readiness for growth both domestically and internationally.”
The policy shift is anticipated to drive clinical research, streamline pathways for FDA approvals, and improve patient access, particularly for those with chronic conditions like pain, epilepsy, and PTSD. Additionally, as U.S. cannabis policy evolves, it could catalyse similar regulatory shifts internationally, expanding trade avenues and enabling U.S. companies to access global markets more seamlessly.
As the cannabis sector undergoes pivotal changes, CANNAVIGIA remains committed to supporting U.S. operators in navigating complex regulations and integrating into the global market. With its robust compliance solutions and international expertise, CANNAVIGIA ensures that U.S. businesses are well-equipped to thrive in an increasingly globalised cannabis industry.
“}]] CANNAVIGIA (by Vigia AG), a global pioneer in cannabis compliance software and consulting, is expanding its presence in the U.S. market, building on recent regulatory developments related to the potential rescheduling of medical cannabis to Schedule III. Read More
